Peter Fong on Genentech’s science shopping list, recent BioNtech deal

December 6, 2016 Christoph Graener

 

Peter Fong, associate director of oncology business development at Genentech Inc. (a division of Roche), speaks to Mike Ward, global director of content for Informa Pharma Intelligence, about his role within the company and the type of deals Genentech is looking for in the cancer space.
Fong explains more about Genentech’s oncology focuses, seeking the best science and how a typical biotech deal works for the company. He also talks about the behind-the-scenes setup for Genentech’s recent multi-million-dollar deal with messenger RNA drug developer, BioNTech AG.

  

  

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Peter Fong – Associate Director, Oncology Business Development, Genentech

 

Previous Article
Vaximm seeks pharma partners for T-cell/checkpoint inhibitor combos
Vaximm seeks pharma partners for T-cell/checkpoint inhibitor combos

Dr. Matthias Schroff, the new CEO of privately-held Swiss vaccines company Vaximm, talks about how the comp...

Next Article
Dimerix CEO explains company’s different drug combo R&D strategy
Dimerix CEO explains company’s different drug combo R&D strategy

Kathy Harrison, CEO of Australian biotech Dimerix, talks about the company's unusual business model, Dimeri...